RESUMEN
Vitamin D has been demonstrated to have an immunomodulatory role in cystic fibrosis with allergic bronchopulmonary aspergillosis (ABPA). Herein, we evaluate supplemental vitamin D in acute-stage ABPA complicating asthma. Thirty subjects were randomised to receive either prednisolone (n = 15, control) or prednisolone and oral vitamin D (n = 15, intervention arm). Serum vitamin D levels were significantly higher in the intervention versus the control arm, following therapy. The mean decline in total IgE at 2 months (primary outcome) was 10% higher in the intervention arm than the control arm; however, this was not statistically significant (48.6% vs 38.1%, P = 0.27). The percentage decline in total IgE after 4 and 6 months of randomisation was also similar in the two arms. There was no difference in asthma exacerbations (0 vs 2, intervention vs control; P = 0.16). No ABPA exacerbation occurred in either arm. The other outcomes including the Th2 (IL-4, IL-6 and IL-10) and Th17 (IL-17) cytokine levels were similar in the two groups. None of the participants experienced hypervitaminosis D. There was no significant improvement in the clinical or immunological outcomes following vitamin D supplementation. A larger trial is required to ascertain the role of vitamin D in ABPA complicating asthma [Clinicaltrials.gov: NCT03133299].
Asunto(s)
Aspergilosis Broncopulmonar Alérgica/tratamiento farmacológico , Aspergilosis Broncopulmonar Alérgica/patología , Asma/tratamiento farmacológico , Asma/patología , Factores Inmunológicos/administración & dosificación , Vitamina D/administración & dosificación , Administración Oral , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Aspergilosis Broncopulmonar Alérgica/complicaciones , Asma/complicaciones , Niño , Citocinas/sangre , Femenino , Humanos , Inmunoglobulina E/sangre , Masculino , Persona de Mediana Edad , Prednisolona/administración & dosificación , Estudios Prospectivos , Resultado del Tratamiento , Adulto JovenRESUMEN
Ravuconazole is a new antifungal triazole with broad-spectrum activity and a long half-life in plasma. We studied the antifungal efficacy, safety, and pharmacokinetics of ravuconazole lysine phosphoester in escalating dosages for the treatment of invasive pulmonary aspergillosis due to Aspergillus fumigatus in persistently neutropenic rabbits. Treatment groups consisted of rabbits treated with ravuconazole at 2.5 (RVC2.5), 5 (RVC5), and 10 (RVC10) mg/kg of body weight/day, rabbits treated with amphotericin B (AMB) at 1 mg/kg/day, or untreated controls. There was a dose-dependent reduction of pulmonary residual fungal burden (CFU per gram) in RVC5-, RVC10-, and AMB-treated rabbits in comparison to untreated controls (P < 0.01, P < 0.001, and P < 0.01, respectively). These findings correlated with progressive galactomannan antigenemia in untreated controls and the RVC2.5-treated rabbits, a lower galactomannan index (GMI) in RVC5- and RVC10-treated rabbits, and a similarly low GMI in AMB-treated rabbits (P < 0.01). Rabbits treated with RVC5, RVC10, and AMB also showed a reduction of organism-mediated pulmonary injury, as measured by infarct scores and lung weights, in comparison to untreated controls (P < 0.001). These results were supported by decreased pulmonary infiltrates detected by computed tomography in RVC5- and RVC10-treated rabbits in comparison to untreated controls (P < 0.05). Survival throughout the entire study was achieved in 95% of RVC5-treated rabbits (P < 0.001), 85% of RVC10-treated rabbits (P < 0.001), and 50% of AMB-treated rabbits (P < 0.05) in comparison to none of the untreated controls. Ravuconazole showed linear plasma pharmacokinetics and a large volume of distribution while maintaining concentrations in plasma above the MIC throughout the dosing interval. There was no evidence of hepatotoxicity or nephrotoxicity among ravuconazole-treated animals. Intravenously administered ravuconazole lysine phosphoester showed dose-dependent efficacy and an excellent safety profile for the treatment of invasive pulmonary aspergillosis in persistently neutropenic rabbits.
Asunto(s)
Antifúngicos/uso terapéutico , Aspergilosis Broncopulmonar Alérgica/tratamiento farmacológico , Neutropenia/complicaciones , Tiazoles/uso terapéutico , Triazoles/uso terapéutico , Anfotericina B/uso terapéutico , Animales , Antifúngicos/efectos adversos , Antifúngicos/farmacocinética , Aspergilosis Broncopulmonar Alérgica/microbiología , Aspergilosis Broncopulmonar Alérgica/patología , Aspergillus fumigatus/efectos de los fármacos , Relación Dosis-Respuesta a Droga , Femenino , Galactosa/análogos & derivados , Semivida , Procesamiento de Imagen Asistido por Computador , Inmunosupresores/farmacología , Inyecciones Intravenosas , Pulmón/microbiología , Pulmón/patología , Mananos/sangre , Pruebas de Sensibilidad Microbiana , Neutropenia/inducido químicamente , Conejos , Análisis de Supervivencia , Sales de Tetrazolio , Tiazoles/efectos adversos , Tiazoles/farmacocinética , Tomografía Computarizada por Rayos X , Triazoles/efectos adversos , Triazoles/farmacocinéticaRESUMEN
C57BL/6 mice were sensitized to Aspergillus fumigatus 1-week culture filtrate, which is rich in the non-glycosylated allergen Asp f1, a major allergen in allergic bronchopulmonary aspergillosis (ABPA). A comparison of the effect of treatment of allergen challenged mice by intranasal administration of a 60-kDa truncated recombinant form of human SP-D (rfhSP-D) or recombinant full length SP-A (rhSP-A) was undertaken. Treatment with rfhSP-D produced significant reduction in IgE, IgG1 and peripheral blood eosinophilia and treatment with rfhSP-D, but not rhSP-A resulted in a significant reduction in airway hyperresponsiveness as measured by whole body plethysmography. Lung histology revealed less peribronchial lymphocytic infiltration in mice treated with rfhSP-D. Intracellular cytokine staining of spleen homogenates showed increases in IL-12 and IFN-gamma and decrease in IL-4. The level of endogenous mouse SP-D was elevated sixfold in the lungs of sensitized mice and was not affected by treatment with rfhSP-D. Taken with our previous studies, with a BALB/c mouse model of ABPA using a 3-week A. fumigatus culture filtrate, the present results show that rfhSP-D can suppress the development of allergic symptoms in sensitized mice independent of genetic background and using a different preparation of A. fumigatus allergens.
Asunto(s)
Alérgenos/inmunología , Antígenos Fúngicos/inmunología , Aspergilosis Broncopulmonar Alérgica/tratamiento farmacológico , Aspergillus fumigatus/inmunología , Proteínas Fúngicas/inmunología , Proteína D Asociada a Surfactante Pulmonar/uso terapéutico , Administración Intranasal , Alérgenos/toxicidad , Animales , Anticuerpos Antifúngicos/biosíntesis , Anticuerpos Antifúngicos/inmunología , Antígenos Fúngicos/toxicidad , Antígenos de Plantas , Aspergilosis Broncopulmonar Alérgica/inducido químicamente , Aspergilosis Broncopulmonar Alérgica/patología , Hiperreactividad Bronquial/inducido químicamente , Hiperreactividad Bronquial/tratamiento farmacológico , Evaluación Preclínica de Medicamentos , Eosinofilia/inducido químicamente , Eosinofilia/tratamiento farmacológico , Femenino , Proteínas Fúngicas/toxicidad , Humanos , Inmunización , Interferón gamma/análisis , Interleucina-12/análisis , Interleucina-4/análisis , Pulmón/patología , Ratones , Ratones Endogámicos BALB C , Ratones Endogámicos C57BL , Fragmentos de Péptidos/administración & dosificación , Fragmentos de Péptidos/farmacología , Fragmentos de Péptidos/uso terapéutico , Pletismografía Total , Proteína A Asociada a Surfactante Pulmonar/análisis , Proteína A Asociada a Surfactante Pulmonar/farmacología , Proteína A Asociada a Surfactante Pulmonar/uso terapéutico , Proteína D Asociada a Surfactante Pulmonar/administración & dosificación , Proteína D Asociada a Surfactante Pulmonar/análisis , Proteína D Asociada a Surfactante Pulmonar/química , Proteína D Asociada a Surfactante Pulmonar/farmacología , Proteínas Recombinantes de Fusión/administración & dosificación , Proteínas Recombinantes de Fusión/farmacología , Proteínas Recombinantes de Fusión/uso terapéutico , Especificidad de la Especie , Bazo/química , Bazo/inmunología , Bazo/patologíaRESUMEN
IL-13 has emerged as a major contributor to allergic and asthmatic responses, and as such it represents an attractive target in these diseases. In this study, IL-13-responsive cells in the lung were targeted via the intranasal administration of IL-13-PE38QQR (IL-13-PE), comprised of human IL-13 and a derivative of Pseudomonas exotoxin, to Aspergillus fumigatus-sensitized mice challenged with A. fumigatus spores, or conidia. Mice received 50, 100, or 200 ng of IL-13-PE or diluent alone (i.e., control group) on alternate days from day 14 to day 28 after the conidia challenge. The control group of mice exhibited significant airway hyperreactivity, goblet cell hyperplasia, and peribronchial fibrosis at day 28 after conidia. Although the two lower doses of IL-13-PE had limited therapeutic effects in mice with fungal-induced allergic airway disease, the highest dose of IL-13-PE tested significantly reduced all features of airway disease compared with the control group. Whole lung mRNA expression of IL-4Ralpha and IL-13Ralpha1 was markedly reduced, whereas bronchoalveolar lavage and whole lung levels of IFN-gamma were significantly elevated in mice treated with 200 ng of IL-13-PE compared with the control group. This study demonstrates that a therapy designed to target IL-13-responsive cells in the lung ameliorates established fungal-induced allergic airway disease in mice.